metyrapone has been researched along with Diabetes Mellitus, Adult-Onset in 7 studies
Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.
metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with metyrapone thus appears a good therapy for AIMAH, but its effectiveness has not, to our knowledge, been studied." | 5.31 | Rational, effective metyrapone treatment of ACTH-independent bilateral macronodular adrenocortical hyperplasia (AIMAH). ( Nomura, K; Obara, T; Omori, K; Omori, N; Takano, K, 2001) |
| "Among this population with Type 2 diabetes high liver fat was associated with hyperinsulinemia, higher fasting glucose levels, peripheral and hepatic insulin resistance, and impaired suppression of FFA oxidation and FFA and glycerol turnover during hyperinsulinemia." | 2.79 | Effects of acute glucocorticoid blockade on metabolic dysfunction in patients with Type 2 diabetes with and without fatty liver. ( Andrew, R; Bastin, ME; Gray, CD; Iredale, JP; Macfarlane, DP; Marshall, I; Preston, T; Raubenheimer, PJ; Walker, BR, 2014) |
| "Treatment with metyrapone thus appears a good therapy for AIMAH, but its effectiveness has not, to our knowledge, been studied." | 1.31 | Rational, effective metyrapone treatment of ACTH-independent bilateral macronodular adrenocortical hyperplasia (AIMAH). ( Nomura, K; Obara, T; Omori, K; Omori, N; Takano, K, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Rose, M | 1 |
| Filiatreault, A | 1 |
| Williams, A | 1 |
| Guénette, J | 1 |
| Thomson, EM | 1 |
| Delivanis, DA | 1 |
| Athimulam, S | 1 |
| Bancos, I | 1 |
| Macfarlane, DP | 1 |
| Raubenheimer, PJ | 1 |
| Preston, T | 1 |
| Gray, CD | 1 |
| Bastin, ME | 1 |
| Marshall, I | 1 |
| Iredale, JP | 1 |
| Andrew, R | 1 |
| Walker, BR | 1 |
| Schiemer, R | 1 |
| Latibeaudiere, M | 1 |
| Close, C | 1 |
| Fox, R | 1 |
| Takeshita, N | 1 |
| Yoshino, T | 1 |
| Mutoh, S | 1 |
| Omori, N | 1 |
| Nomura, K | 1 |
| Omori, K | 1 |
| Takano, K | 1 |
| Obara, T | 1 |
| Atiea, JA | 1 |
| Aslan, SM | 1 |
| Owens, DR | 1 |
| Luzio, S | 1 |
1 trial available for metyrapone and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Effects of acute glucocorticoid blockade on metabolic dysfunction in patients with Type 2 diabetes with and without fatty liver.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Metabolism | 2014 |
6 other studies available for metyrapone and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Modulation of insulin signaling pathway genes by ozone inhalation and the role of glucocorticoids: A multi-tissue analysis.
Topics: Animals; Diabetes Mellitus, Type 2; Glucocorticoids; Insulin; Male; Metyrapone; Ozone; Rats; Rats, I | 2023 |
Modern Management of Mild Autonomous Cortisol Secretion.
Topics: 14-alpha Demethylase Inhibitors; Adrenal Cortex Neoplasms; Adrenal Insufficiency; Adrenalectomy; Adr | 2019 |
Type 2 diabetes identified in pregnancy secondary to Cushing's syndrome.
Topics: Adenoma; Adrenal Gland Neoplasms; Adrenal Glands; Adult; Cushing Syndrome; Diabetes Mellitus, Type 2 | 2011 |
Possible involvement of corticosterone in bone loss of genetically diabetic db/db mice.
Topics: Animals; Body Weight; Bone Density; Bone Diseases, Metabolic; Calcium; Corticosterone; Diabetes Mell | 2000 |
Rational, effective metyrapone treatment of ACTH-independent bilateral macronodular adrenocortical hyperplasia (AIMAH).
Topics: Adrenal Glands; Cushing Syndrome; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Humans; Hydrocortiso | 2001 |
Early morning hyperglycaemia "dawn phenomenon" in non-insulin dependent diabetes mellitus (NIDDM): effects of cortisol suppression by metyrapone.
Topics: Aged; Blood Glucose; C-Peptide; Circadian Rhythm; Diabetes Mellitus, Type 2; Epinephrine; Female; Gl | 1990 |